Biotech is big business.

Deal after deal, Eli Lilly and Co. is using the fruits of its success from developing blockbuster GLP-1 medicines to prepare for its next chapter and build a bridge over a looming patent cliff. Since ...

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

Kelonia Therapeutics has shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech. All 18 ...

Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing ...

The world’s most popular weight-loss and diabetes drugs are linked to a powerful new possible benefit: better outcomes for cancer patients. A suite of four new studies suggests that people taking ...

However, Eli Lilly launched its own weight loss pill, orforglipron, marketed as Foundayo, in April. And the company has another drug candidate, retatrutide, that targets GLP-1 and GIP receptors, as ...

Eli Lilly announced Tuesday that it is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., in deals ...

Eli Lilly agreed to acquire Bothell, Wash.-based Curevo Vaccine for up to $1.5 billion in cash.

May 21 (UPI) --Eli Lilly said its weight loss drug, retatrutide, helped nearly half of participants in a phase 3 trial to lose more than 30% of their weight. Many of the people who lost that much ...